查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1970971

胞漿素原原市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Plasminogen Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球胞漿素原市場預計將從 2025 年的 27.9 億美元成長到 2031 年的 38.3 億美元，複合年成長率為 5.42%。

胞漿素原原是一種糖蛋白前體，可轉化為胞漿素，纖溶酶是一種對纖維蛋白溶解和創傷治療至關重要的酶。市場主要集中在用於治療先天性I型胞漿素原原缺乏症和褐煤結膜炎的濃縮製劑。市場成長的關鍵促進因素包括：透過先進的基因篩檢來提高罕見凝血障礙的識別率，以及特定替代療法獲得越來越多的監管核准。這些基本的醫療需求正在形成持續的需求基礎，這與暫時的市場趨勢截然不同。

市場概覽
預測期 2027-2031
市場規模：2025年 27.9億美元
市場規模：2031年 38.3億美元
複合年成長率：2026-2031年 5.42%
成長最快的細分市場 眼藥水
最大的市場 北美洲

然而，該領域面臨著許多挑戰，包括原料血漿供應有限以及血漿分離過程的高昂資本投入，這些都限制了能夠生產此類療法的製造商數量。這種集中化降低了供應彈性，並導致治療成本居高不下。根據血漿蛋白治療協會預測，到2024年，其成員公司將生產全球60%以上的血漿蛋白療法。這種高度集中的生產模式凸顯了供應鏈的脆弱性，不僅造成供不應求的風險，還可能阻礙市場擴張和提高藥物可近性。

市場促進因素

全球胞漿素原市場的主要促進因素是新型替代療法的監管核准和生產基礎設施的策略性擴張。從藥房配製產品過渡到經FDA核准的生技藥品需要對分餾設施進行大量資本投資，以確保穩定的供應。根據Kedrion BioPharma於2024年11月發布的新聞稿，美國FDA核准該公司位於義大利博洛尼亞的生產基地生產「Liplazim」是一項關鍵進展。這項里程碑式的核准將克服供應瓶頸，並有助於擴大生產以滿足全球需求。高准入門檻也體現在所需的財務規模上。根據Kedrion BioPharma於2024年4月發布的2023會計年度年度報告，該公司營收達到14億歐元，凸顯了能夠維持如此專業化業務的公司的綜合實力。

同時，眼科臨床適應症的擴展正成為提高患者診斷率的關鍵催化劑。木樣結膜炎常被觀察到是先天性缺陷的前驅症狀，有助於辨識潛在的先天缺陷。根據Kedrion BioPharma公司2024年5月發布的公告“Ryplazim在美國上市”，約81%的先天性胞漿素原原缺乏症患者以單眼或雙眼病變為首發症狀。透過關注這一臨床症狀，臨床醫生正在縮小診斷差距，加快患者識別速度，並確立明確的醫療需求，這將有助於保險報銷和終身替代療法的市場滲透。

市場挑戰

由於原料血漿供應有限以及分離製程的高資本投入，全球胞漿素原市場面臨許多障礙。這些障礙有效地限制了能夠生產纖溶酶原的生產商數量，形成了一個集中化的市場結構，導致供應難以跟上不斷成長的需求。這種市場僵化降低了供應彈性，造成治療成本居高不下，並限制了病患的就醫途徑，尤其是在國內採血設施不發達的地區。

生產和採集基礎設施的集中化導致供應鏈存在顯著的脆弱性。血漿供應的地域不平衡直接限制了可用於加工的原料數量，從而阻礙了市場成長。根據血漿蛋白治療協會2024年的報告，其成員公司在歐盟境內營運約160個血漿捐贈中心。主要市場本地採集點數量相對較少，凸顯了對進口血漿的高度依賴，造成了物流瓶頸。因此，無法在不同地區快速擴大原料採集規模，成為限制產業成長潛力的主要因素。

市場趨勢

纖溶酶原在糖尿病足潰瘍和創傷護理管理的臨床應用不斷擴展，這標誌著全球纖溶酶原市場迎來了一個變革性的轉折點，使該行業的關注點從傳統的罕見先天缺陷轉向高發慢性疾病領域。製造商正在利用纖溶酶原的促發炎和免疫調節特性，加速開發用於治療難癒合傷口的再生醫學療法。與I型先天缺陷相比，該領域的潛在患者群體大得多。為了支持這一商業性趨勢，Omnio AB於2025年5月發布的新聞稿《籌集430萬歐元以加速創傷治療藥物的臨床進展》指出，該公司已獲得430萬歐元資金，用於完成重組胞漿素原原候選藥物（特別是用於治療慢性傷口的藥物）的GMP生產並推進臨床試驗。

同時，為擴大商業分銷管道，夥伴關係的拓展正在重塑市場的物流基礎設施，以克服罕見疾病治療固有的可及性障礙。由於生產集中在少數幾家全球分餾企業，這些公司正尋求與專業經銷商建立策略合作夥伴關係，以確保產品在國際範圍內的穩定供應。 Kedrion BioPharma 於 2025 年 3 月發布的「Kedrion 拓展 Liplagym 分銷網路」公告便是這一趨勢的典型例證。該公告將包括 Curascrit SD 和 CVS Health 在內的三家重要的專業藥房合作夥伴納入其美國分銷網路，旨在最佳化患者獲得胞漿素原替代療法的途徑。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球胞漿素原原市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（靜脈注射、眼藥水）
    • 外用（角膜結膜炎、糖尿病足部病變、創傷治療等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美胞漿素原原市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲胞漿素原原市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區胞漿素原市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲胞漿素原原市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：胞漿素原在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球胞漿素原原市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Boehringer Ingelheim Inc. GmbH
  • Kedrion SpA
  • Genentech
  • Prometic Life Sciences Inc
  • Grifols, SA
  • Octapharma AG
  • Green Cross Corporation
  • Baxter International Inc.
  • CSL Behring LLC
  • Renaissance Acquisition Holdings LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19040

The Global Plasminogen Market is projected to expand from USD 2.79 Billion in 2025 to USD 3.83 Billion by 2031, reflecting a CAGR of 5.42%. Plasminogen is a glycoprotein zymogen that converts to plasmin, an enzyme vital for fibrinolysis and wound healing, with the market focusing primarily on therapeutic concentrates for treating congenital Type I plasminogen deficiency and ligneous conjunctivitis. Market growth is chiefly driven by the enhanced identification of rare coagulation disorders through advanced genetic screening and the increasing regulatory approval of specific replacement therapies. These fundamental medical necessities create a sustainable demand foundation that is distinct from transient market trends.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.79 Billion
Market Size 2031USD 3.83 Billion
CAGR 2026-20315.42%
Fastest Growing SegmentEye Drops
Largest MarketNorth America

However, the sector faces a substantial challenge regarding the limited supply of source plasma and the high capital barriers associated with fractionation, which restricts the number of capable manufacturers. This consolidation results in low supply elasticity and sustains high therapy costs. According to the 'Plasma Protein Therapeutics Association', in '2024', member companies produced over 60 percent of the plasma protein therapies used worldwide. This centralized production capacity underscores a supply chain vulnerability that creates risks of shortages and may impede broader market expansion and accessibility.

Market Driver

The primary forces propelling the global plasminogen market are regulatory approvals for novel replacement therapies and the strategic expansion of manufacturing infrastructure. The transition from compounding pharmacy formulations to FDA-approved biologicals requires immense capital investment in fractionation facilities to ensure a consistent supply. A pivotal development occurred when, according to a November 2024 corporate press release by Kedrion Biopharma, the U.S. FDA approved the company's manufacturing facility in Bolognana, Italy, to produce Ryplazim. This milestone allows for production scaling to meet global demand, overcoming supply bottlenecks. The high barriers to entry are evidenced by the financial scale required; according to Kedrion Biopharma's 'Annual Report 2023' released in April 2024, the company generated revenues of 1.4 billion Euro, highlighting the consolidated nature of players capable of sustaining such specialized operations.

Simultaneously, the expansion of clinical indications in ophthalmology is acting as a critical catalyst for increasing patient diagnosis. Ligneous conjunctivitis is often the sentinel symptom leading to the identification of the underlying congenital deficiency. According to the 'Ryplazim Now Available in US' announcement by Kedrion Biopharma in May 2024, approximately 81 percent of patients with congenital plasminogen deficiency develop lesions on one or both eyes as their lead symptom. By focusing on this clinical presentation, clinicians are narrowing the diagnostic gap, accelerating patient identification, and establishing a clear medical necessity that drives insurance reimbursement and consistent market uptake for lifelong replacement therapies.

Market Challenge

The Global Plasminogen Market faces a substantial obstacle due to the finite supply of source plasma and the intense capital requirements for fractionation. These barriers effectively limit the number of capable manufacturers, leading to a consolidated market structure where supply cannot easily adjust to rising demand. This rigidity creates low supply elasticity, maintaining high costs for therapies and restricting accessibility for patients, particularly in regions without established domestic collection capabilities.

This concentration of production and collection infrastructure introduces critical vulnerabilities into the supply chain. The market's growth is directly hampered by the geographic imbalance of plasma availability, which limits the volume of raw material available for processing. According to the 'Plasma Protein Therapeutics Association' in '2024', member companies operated approximately 160 plasma donation centers in the European Union. This relatively low number of local collection points in a major market underscores the heavy reliance on imported plasma, which creates logistical bottlenecks. Consequently, the inability to rapidly scale raw material collection in diverse regions serves as a hard ceiling on the industry's expansion potential.

Market Trends

The expansion of clinical applications into Diabetic Foot Ulcer and Wound Care Management represents a transformative shift for the Global Plasminogen Market, moving the industry beyond its traditional focus on rare congenital deficiencies toward high-volume chronic indications. Manufacturers are increasingly leveraging the pro-inflammatory and immunoregulatory properties of plasminogen to develop regenerative therapies for non-healing wounds, a segment with a substantially larger addressable patient population than Type I deficiency. Validating this commercial trajectory, according to Omnio AB's May 2025 press release 'Omnio raises €4.3 Million to accelerate wound-healing drug to clinical stage', the company secured €4.3 million to finalize GMP manufacturing and advance its recombinant plasminogen candidate into clinical trials specifically for chronic wound management.

Simultaneously, the establishment of cross-border partnerships for expanded commercial distribution is reshaping the market's logistical framework to overcome the accessibility barriers inherent to rare disease therapies. As production consolidates among a limited number of global fractionators, companies are forging strategic alliances with specialized distributors to ensure consistent product availability across international jurisdictions. Exemplifying this trend, according to the 'Kedrion Expands Ryplazim Distribution Network' announcement by Kedrion Biopharma in March 2025, the company integrated three major specialty pharmacy partners, including CuraScript SD and CVS Health, into its United States network to optimize patient access to its plasminogen replacement therapy.

Key Market Players

  • Boehringer Ingelheim Inc. GmbH
  • Kedrion S.p.A
  • Genentech
  • Prometic Life Sciences Inc
  • Grifols, S.A
  • Octapharma AG
  • Green Cross Corporation
  • Baxter International Inc.
  • CSL Behring LLC
  • Renaissance Acquisition Holdings LLC

Report Scope

In this report, the Global Plasminogen Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plasminogen Market, By Type

  • Intravenous Injection
  • Eye Drops

Plasminogen Market, By Application

  • Ligneous Conjunctivitis
  • Diabetic Foot
  • Wound Healing
  • Others

Plasminogen Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasminogen Market.

Available Customizations:

Global Plasminogen Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plasminogen Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Intravenous Injection, Eye Drops)
    • 5.2.2. By Application (Ligneous Conjunctivitis, Diabetic Foot, Wound Healing, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Plasminogen Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Plasminogen Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Plasminogen Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Plasminogen Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Plasminogen Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Plasminogen Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Plasminogen Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Plasminogen Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Plasminogen Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Plasminogen Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Plasminogen Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Plasminogen Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Plasminogen Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Plasminogen Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Plasminogen Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Plasminogen Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Plasminogen Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Plasminogen Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Plasminogen Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Plasminogen Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Plasminogen Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Plasminogen Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Plasminogen Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Plasminogen Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Plasminogen Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Boehringer Ingelheim Inc. GmbH
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Kedrion S.p.A
  • 15.3. Genentech
  • 15.4. Prometic Life Sciences Inc
  • 15.5. Grifols, S.A
  • 15.6. Octapharma AG
  • 15.7. Green Cross Corporation
  • 15.8. Baxter International Inc.
  • 15.9. CSL Behring LLC
  • 15.10. Renaissance Acquisition Holdings LLC

16. Strategic Recommendations

17. About Us & Disclaimer